[{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Taro Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Taro Pharmaceuticals"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Juyou Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Juyou Biotechnology"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Croma-Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ Croma Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Croma Pharma"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Crescita Therapeutics \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ STADA"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Egis Pharmaceuticals PLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Crescita Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Crescita Therapeutics \/ Egis Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Crescita Therapeutics \/ Egis Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Tetracaine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the app...

                          Brand Name : Pliaglis

                          Molecule Type : Small molecule

                          Upfront Cash : $0.7 million

                          December 13, 2021

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Egis Pharmaceuticals PLC

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the Agreement, STADA will be responsible for commercializing Pliaglis in the Territories utilizing its experienced sales force.

                          Brand Name : Pliaglis

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 18, 2021

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : STADA Arzneimittel

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other mi...

                          Brand Name : Pliaglis

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 28, 2021

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Croma-Pharma

                          Deal Size : $1.4 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.

                          Brand Name : Pliaglis

                          Molecule Type : Small molecule

                          Upfront Cash : $0.1 million

                          November 05, 2020

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Juyou Biotechnology

                          Deal Size : $2.9 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

                          Brand Name : Pliaglis

                          Molecule Type : Small molecule

                          Upfront Cash : $3.9 million

                          July 28, 2020

                          Lead Product(s) : Lidocaine,Tetracaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Taro Pharmaceutical Industries

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank